Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Location

MS status

Recruitment Status

Phase

Drugs

Prior Immunotherapy Allowed

NCT ID

Title key word search

Date Trial Added

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Phase	Date Added	Location	Prior IO Allowed	CRC-directed	Status	Drugs	Tags
NCT ID NCT03727763	TitleCetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E Mutated Advanced Colorectal Cancer (IMPROVEMENT)	Phase Phase 2	Date Added 2018-11-01	Location China	Prior IO Allowed No	CRC-directed Yes	Status Recruiting	Drugs cetuximab, Vemurafenib	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT04092673	TitleStudy of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies	Phase Phase 1	Date Added 2019-09-17	Location California, United States Michigan, United States Nevada, United States New Jersey, United States New York, United States Ohio, United States Texas, United States Virginia, United States	Prior IO Allowed No	CRC-directed No	Status Recruiting	Drugs eFT226, eFT226	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT02864485	TitleLiving Donor Liver Transplantation for Unresectable Colorectal Cancer Liver Metastases	Phase Not Applicable	Date Added 2016-08-12	Location Canada	Prior IO Allowed No	CRC-directed Yes	Status Recruiting	Drugs	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03577665	TitleCurative Proton Beam Therapy for Patients With Liver Metastasis of Colorectal Cancer	Phase Not Applicable	Date Added 2018-07-05	Location Korea, Republic of	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT04110093	TitleRegorafenib Plus PD-1 Inhibitor in Patients With Colorectal Cancer	Phase Phase 1/Phase 2	Date Added 2019-10-01	Location China	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs Regorafenib and PD-1 inhibitor	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT04589845	TitleTumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study	Phase Phase 2	Date Added 2020-10-19	Location Alabama, United States Arizona, United States California, United States Colorado, United States Delaware, United States Florida, United States Georgia, United States Idaho, United States Illinois, United States Indiana, United States Maine, United States Maryland, United States Michigan, United States Minnesota, United States Missouri, United States Montana, United States Nebraska, United States Nevada, United States New Hampshire, United States New Jersey, United States New Mexico, United States New York, United States Ohio, United States Oregon, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Washington, United States Wisconsin, United States Australia Belgium Brazil Canada China Denmark France Germany Hong Kong Israel Italy Japan New Zealand Poland Portugal Puerto Rico Singapore South Africa South Korea Spain Switzerland Taiwan United Kingdom	Prior IO Allowed No	CRC-directed No	Status Recruiting	Drugs Alectinib, Atezolizumab, Belvarafenib, Entrectinib, Idasanutlin, Inavolisib, Ipatasertib, Pralsetinib, Trastuzumab emtansine	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03668431	TitleDabrafenib + Trametinib + PDR001 In Colorectal Cancer	Phase Phase 2	Date Added 2018-09-12	Location Massachusetts, United States	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs Dabrafenib, PDR001, Trametinib, Mekinist, Tafinlar	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT02925234	TitleThe Drug Rediscovery Protocol (DRUP Trial)	Phase Phase 2	Date Added 2016-10-05	Location Netherlands	Prior IO Allowed Yes	CRC-directed No	Status Recruiting	Drugs Abemaciclib, afatinib, Alectinib, Alpelisib, Atezolizumab and Bevacizumab, Axitinib, Cabozantinib, Crizotinib, Dabrafenib, Dabrafenib and trametinib, Dacomitinib, durvalumab, Entrectinib, Erdafitinib, Erlotinib, Ipilimumab and nivolumab, Lenvatinib, lorlatinib, Nilotinib, Nivolumab, Olaparib, palbociclib, panitumumab, Pembrolizumab, Regorafenib, ribociclib, Rucaparib, Sunitinib, Talazoparib, Trametinib, Trastuzumab and Pertuzumab (combination treatment), Vemurafenib and Cobimetinib (combination treatment), Vismodegib	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT02215889	TitlePartial Liver Segment 2/3 Transplantation Study	Phase Phase 1	Date Added 2014-08-13	Location Norway	Prior IO Allowed No	CRC-directed Yes	Status Recruiting	Drugs	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT04085185	TitleA Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI110 in Subjects With Advanced Malignant Tumors	Phase Phase 1	Date Added 2019-09-11	Location China	Prior IO Allowed Yes	CRC-directed No	Status Recruiting	Drugs IBI110, IBI110+ Sintilimab, IBI110, Sintilinab	Tags MSI-H/ MMRd, MSS/ MMRp

Showing 51 to 60 of 299 entries